US EditionPalatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice
- Palatin Technologies, Inc. Announced on May 7, 2025, that NYSE American initiated delisting proceedings against its common stock and suspended trading immediately.
- The delisting notice attributes Palatin's removal to the common stock's low trading price, leading the company to prepare an appeal before the May 14, 2025 deadline.
- Palatin, a biopharmaceutical company focused on developing melanocortin receptor-targeted treatments, announced that starting May 8, 2025, its common shares will move to trading on the OTC Pink tier under the symbol PTNT.
- President and CEO Carl Spana conveyed his dissatisfaction with the delisting decision, emphasizing the company’s valuable assets and reaffirming their dedication to moving forward with the business plan despite the setback.
- The company’s appeal could affect its listing status, but there is no guarantee of success, while the transition to OTC Pink marks a significant change in Palatin's market presence.
Insights by Ground AI
Does this summary seem wrong?
57 Articles
57 Articles
All
Left
6
Center
20
Right
7
Coverage Details
Total News Sources57
Leaning Left6Leaning Right7Center20Last UpdatedBias Distribution61% Center
Bias Distribution
- 61% of the sources are Center
61% Center
L 18%
C 61%
R 21%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
